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Summary: We evaluated the clinical usefulness of a commercial two-site immunoassay for calcitonin, which
is based on two monoclonal antibodies against distinct epitopes of calcitonin. The potential lower detection
limit of the assay was 2 ng/1. Inter-assay and intra-assay variation were both < 11%. No cross reaction with
calcitonins from different species (salmon and eel calcitonin) was found. Of the various fragments of human
calcitonin, only the 11 — 32 fragment could be detected.
Basal calcitonin concentrations in normals (n = 69) ranged from < 2 ng/1 to 50 ng/1. Basal calcitonin
concentrations in 30% of the men (< 2—48 ng/1) and 51% of the women (< 2 — 10 ng/1) were undetectable.
Stimulation of calcitonin with pentagastrin (0.5 g/kg body weight) in normal subjects was followed by an
increase in calcitonin in all men (n = 17) and in 60% of the women (n =12). The upper reference value for
pentagastrin-stimulated calcitonin concentrations for all 29 normals was 78 ng/1 (defined as the 95th percentile):
79 ng/1 for men, and 50 ng/1 for women. Using a different immunoradiometric two-site assay, a similar
percentage of "positive" responses to pentagastrin in normals was obtained (20 out of 29).
Four previously thyroidectomized patients with medullary thyroid carcinoma had normal basal, but patho-
logical stimulated calcitonin values at follow-up. At reoperation, cervical lymph nodes with tumour tissue
were removed. Postoperatively, the patients had basal and stimulated calcitonin concentrations within the
limits of the established reference range.
In conclusion, reference ranges for basal and pentagastrin-stimulated calcitonin concentrations have been
established for an immunometric two-site assay. This allows a safer discrimination between normal and
pathologically stimulated calcitonin concentrations. This may lead to a better definition of cured patients and
perhaps an earlier diagnosis of medullary thyroid carcinoma in familial screening.
Introduction . .r ·background concentrations may mask significant
For diagnosis, screening and follow-up of medullary changes in calcitonin concentration (3 — 5). Some of
carcinoma of the thyroid, calcitonin is commonly these problems have been overcome to some extent
determined in unextracted samples of plasma or serum by the improvement and evaluation of analytical pro-
by radioimmunoassay with polyclonal antibodies (1, cedures, but physiological concentrations of plasma
2). Measurement of calcitonin by conventional ra- calcitonin are low and still usually undetectable by
dioimmunoassays, however, still presents problems, conventional radioimmunoassays (2, 6). Therefore
Thus, multiple heterogeneous forms of circulating im- small changes in circulating calcitonin remain below
munoreactive calcitonin, which are variably detected the detection limit and may be missed. This is of
by polyclonal antisera, mainly account for the wide particular concern in screening for patients with fam-
range of reported reference values, and their high ilial medullary thyroid carcinoma, in which circulating
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basal calcitonin concentrations often do not differ
from the reference range. In this setting provocative
tests with pentagastrin or calcium infusion are still
necessary (2, 7).
The new generation of two-site immunoassays using
two monoclonal antibodies against distinct epitopes
of human calcitonin have largely improved both the
sensitivity and the specifity of calcitonin determina-
tion (8, 9). These assays are now commercially avail-
able, but little is known regarding their clinical su-
periority, particularly the reference range for penta-
gastrin tests. Therefore we established a reference
range for pentagastrin-stimulated calcitonin concen-
trations and evaluated the clinical usefulness of two,
new, commercially available immunometric assays
(one immunoradiometric assay and one enzyme im-
munometric assay).
Materials and Methods
Two-site assays for calcitonin
Calcitonin concentrations were determined by a sob'd phase
two-site enzyme immunometric assay (Medgenix, Düsseldorf,
Germany). Calcitonin is captured by a monoclonal antibody
directed against it and immobilized on microtitre plates. De-
tection is performed using a second monoclonal antibody la-
belled with horseradish peroxidase. The assay requires incu-
bation of the sample overnight at 4 °C, followed by a short
incubation of 15 min after five washing steps. Serum, heparin-
ized plasma or EDTA plasma may be used without extraction.
The lower potential detection limit of the assay was determined
and defined as the point of the calibration curve 3 standard
deviations above B0 (based on 16 measurements of the 0-
standard). To obtain intra- and inter-assay variations, samples
with known concentrations of calcitonin (10—613 ng/1) were
repeatedly measured in eight separate assays and simultane-
ously measured eight times in one assay. Samples from five
patients with medullary thyroid carcinoma and high concentra-
tions of basal calcitonin were serially diluted in calcitonin-free
medium (provided with the assay) to estimate linearity of the
assay in the range of measurement (2—1000 ng/1). The speci-
ficity was tested by assaying various concentrations of calci-
tonin from salmon and eel and various concentrations of dif-
ferent fragments of human calcitonin.
The fragments of human calcitonin and eel calcitonin were a
gift from Dr. Kabay, Ciba Geigy, Basel, Switzerland; salmon
calcitonin was a gift from Sandoz, Nürnberg, Germany.
Additionally, basal and pentagastrin stimulated calcitonin con-
centrations in 29 normals were also measured by a commercially
available immunoradiometric two-site assay of calcitonin
(ELSA-hCT, CIS, Dreieich, Germany). The assay is based on
two monoclonal antibodies (8) against calcitonin (calcitonin
sequences 11 — 17 and 24—32), uses a single incubation step
and has a detection limit of 2 ng/1.
Samples
Basal calcitonin concentrations were determined in 69 healthy
subjects (26 women, 43 men, age 20 — 70 years) and in 9 thy-
roidectomized patients. In 29 healthy volunteers (17 men, 12
women, age 20 — 50 years), who gave informed consent, a pen-
tagastrin stimulation test was performed: 0.5 g pentagastrin
(Gastrodiagnost®, Merck, Darmstadt, Germany) per kg body
weight was injected intravenously within 5 s and blood samples
were drawn at 5 minutes before and 0, 2, 5, 10, 20 and 30 min
after injection.
In four patients with histologically confirmed medullary thyroid
carcinoma, both the basal and the pentagastrin-stimulated con-
centrations of calcitonin were determined before and after re-
operation.
Results
Assay characteristics
The lowest detectable calcitonin concentration was
1.7 ng/1 (for practical reasons 2 ng/1). This was com-
parable with the detection limit of 2 ng/1 of the im-
munoradiometric assay used for comparison (CIS).
The inter-assay variation was 5.8% for 25 ng/1, 9.9%
for 134 ng/1 and 7.2% for 613 ng/1. The intra-assay
variation was 11.2% for 10 ng/1, 5.8% for 25 ng/1
and 2.4% for 134 ng/1. The recovery of the assay
proved to be linear over a braod range of concentra-
tions (2 — 1000 ng/1) as tested by dilution of samples
from patients with known medullary thyroid carci-
noma (fig. 1). In order to test the specificity, the cross-
reactivities of different fragments of human calcitonin
and calcitonin of different species were tested. The
intact molecule 1—32 and the fragment 17 — 32 cross-
reacted (99.6% and 120%, respectively). The human
calcitonin-fragments 1 — 10 and 11—23 were not de-
tectable up to concentrations of 300 pmol/1. Salmon
calcitonin and eel calcitonin displaced the human
1—32 tracer by up to 8% at concentrations of 300
pmol/1, i. e. the assay is 200-fold less sensitive for fish
calcitonin than for human calcitonin.
10000
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Fig. 1. Serial dilution of samples from patients with medullary
thyroid carcinoma showing linearity in the range of
10—2000 ng/1; y-axis shows calcitonin concentration, x-
axis shows the dilution factor.
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Fig. 2. Basal concentrations of calcitonin in 69 healthy subjects
(43 men, 26 women) and 9 thyroidectomized patients.
The horizontal line indicates the 95th percentile for both
women and men.
Basal calcitonin concentrations
Basal calcitonin concentrations were detectable
(> 2 ng/1) in 60% of 69 healthy subjects, and ranged
from < 2 ng/1 to 50 ng/1. The mean value was 8.4
±13 ng/1 (undetectable value set as 2 ng/1), but the
values were not normally distributed. The median was
4 ng/1 with a 95th percentile of 48 ng/1 as the upper
limit. Values were higher in men than in women, the
95th percentile for women being 10 ng/1 and for men
49 ng/1. In the male group 23% of all values were
undetectable, whereas in the female group 42% of the
values were below the detection limit (fig. 2). Serum
values from eight of nine thyroidectomized patients
were below the detection limit.
Calcitonin concentrations after stimulation
In 29 healthy persons a rapid intravenous injection
of pentagastrin (0.5 μg/kg body weight) resulted in
an acute rise of calcitonin concentrations within 2—5
min, which declined to basal values 10 minutes after
the injection (fig. 3). The calcitonin concentrations
after pentagastrin stimulation ranged from undetect-
able (< 2 ng/1) to 135 ng/1. In all men, the stimulated
calcitonin concentrations were within the detectable
range, whereas basal calcitonin concentrations were
only detectable in 77%. The percentage of women
with detectable calcitonin concentrations increased
from 49% (basal) to 60% (after pentagastrin stimu-
lation). Since the values were not equally distributed,
the 95th percentile was used to establish the upper
limit of normal. The 95th percentile for stimulated
calcitonin concentrations was 50 ng/1 for women, 79
ng/1 for men and 78 ng/1 for both (tab. 1).
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Fig. 3. Pentagastrin Stimulation (l) in normals (n = 29);
a) men (n = 17), b) women (n = 12). The 95th percentile
(shaded area) and the median (open squares) are given.
Tab. 1. Comparison between immunoenzymetric (Medgenix)
and immunoradiometric (CIS) assays for calcitonin in
29 normals. Basal calcitonin concentrations and values
after pentagastrin-stimulation are shown in ng/1.
Calcitonin
assays
Men (n = 17) Women (n = 12)
Basal After Basal After
stimula- stimula-
tion tion
Immuno-
enzymetric
assay
(Medgenix®)
Immuno-
95th
percentile
Median
95th
10.7
2.1
6.2
79
13.1
66.3
17
2.3
15.3
49.5
13.4
24.4
radiometric percentile
assay
(CIS®) Median 2.3 6.8 2.7 5.4
Using the immunoradiometric two-site assay for the
same 29 pentagastrin stimulation tests, a similar in-
crease due to pentagastrin stimulation was found (tab.
1). '''Positive" responses to pentagastrin (defined as
an increase from < 2 ng/1 to > 2 ng/1 or more than
a two-fold increase in detectable values) were detected
with the same frequency by both assays (19/29 in the
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enzyme immunometric assay vs. 20/29 in the immu-
noradiometric assay). The correlation coefficient be-
tween the basal and stimulated calcitonin concentra-
tions of both assays was r = 0.7.
Calcitonin concentrations in patients with
medullary thyroid carcinoma
In four patients with medullary thyroid carcinoma
who underwent total thyroidectomy, basal calcitonin
concentrations, as determined with the enzyme im-
munometric assay, were within the normal range, but
a pathological increase after pentagastrin stimulation
was observed (range: 443 — > 900 ng/1), which clearly
exceeded the reference range (tab. 2). After reopera-
tion, calcitonin concentrations before and after pen-
tagastrin stimulation were within the reference range.
Apparently these patients were cured with respect to
biochemical criteria; only one patient still showed
slightly increased calcitonin concentrations after pen-
tagastrin stimulation.
Tab. 2. Basal calcitonin concentrations and values after pen-
tagastrin stimulation of thyroidectomized patients with
medullary thyroid carcinoma before and after reoper-
ation.
Patient
Sex
Preoperative
calcitonin
concentrations
1 <f
2 <f
3 9
4 c?
(ng/1)
Basal
74
38
7
23
Penta-
gastrin
stimu-
lation
918
922
443
935
Postoperative
calcitonin
concentrations
(ng/1)
Basal
3
1
2
12
Penta-
gastrin
stimu-
lation
2
14
131
73
Discussion
The tested enzyme immunometric calcitonin assay
(Medgenix) provides rapid and reliable results without
time consuming extraction methods. The lower detec-
tion limit of 2 ng/1 is better than the lower detection
limit of the standard radioimmunoassays and equi-
valent to that of the first immunometric assay for
calcitonin using monoclonal antibodies described by
Motte et al. (8, 9). The assay antibodies did not cross-
react significantly with calcitonin from other species
or human calcitonin fragments, except for human
calcitonin fragment 11—32. Apparently both anti-
bodies recognize epitopes within the sequence 11 — 32
of the calcitonin molecule or fragments which are
longer than human calcitonin 10 — 32. This is in agree-
ment with the theoretical expectation based on the
utilization of monoclonal antibodies against the epi-
topes of amino acids 11 — 13 and 30 — 32. Since the
latter epitope is only accessible on the mature form
of the hormone (8), the assay should be specific for
the mature circulating form of calcitonin.
Despite the high sensitivity of the assay, only 65% of
the basal calcitonin concentrations in control subjects
were detectable. Consistent with the fact that, in gen-
eral, women have lower calcitonin concentrations (10)
and with the results of Perdrisot et al. (11), the per-
centage of undetectable values is higher in women.
With the modified assay of Motte et al., 83% of
control persons had undetectable basal concentrations
of calcitonin (< 5 ng/1) (11, 12). Comparing the per-
centage of undetectable calcitonin concentrations is
difficult, however, as no information is given about
the sex and age of the control group.
In our study, all men responded with a measurable
increase of calcitonin concentrations after pentagas-
trin stimulation. In women, the percentage of detect-
able values increased from 49% to 60%, so that 40%
were still undetectable. In agreement with our results,
Perdrisot et al. (11) also found a measurable increase
of calcitonin concentrations in 50% of his subjects.
The immunoradiometric assay (CIS) revealed in-
creases during pentagastrin tests in normal subjects
(20/29), which were similar to those measured with
the enzyme immunometric assay (19/29), according
to our definition of "positive" pentagastrin tests. Us-
ing the same assay, Weissei et al. (13) even reported
measurable basal and stimulated calcitonin concen-
trations in all subjects tested, but his number of con-
trol subjects was very small (n = 4). Interestingly the
absolute increases in calcitonin concentrations in our
volunteers were much higher than those reported by
Perdrisot et al. or Weissei et al. (11, 13). We found a
maximum of 135 ng/1 in one healthy man after stim-
ulation, whereas the maximal increase of calcitonin
reported by Perdrisot et al. was only 30 ng/1. There
might be several explanations for this discrepancy.
The enzymatic assay might be prone to unspecific
interferences or due to slightly modified assay pro-
tocols (13). However, it is difficult to compare abso-
lute concentrations of calcitonin after stimulation
since a slow injection rate of pentagastrin (over 3 min)
(11) has been used in the literature. We found the
most distinct increase of calcitonin 2 min after a bolus
injection of pentagastrin within 5 s; therefore the dis-
crepancy is at least to some extent due to a slower
injection rate of pentagastrin.
A major advantage of the tested assays is the precise
definition of the upper normal limit for stimulated
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calcitonin concentrations. We used the 95th percentile
to define a reference range for stimulated calcitonin
concentrations in normal subjects, as the values after
stimulation were not equally distributed. In 4 out of
20 normal subjects deviating peak concentrations
have been reported in the literature after stimulation
with calcium combined with pentagastrin (14). We did
not observe any widely deviating peak concentration
in our study.
Four of our previously operated patients with med-
ullary thyroid carcinoma had basal calcitonin concen-
trations within the normal range; the increase after
pentagastrin, however, was rapid and largely exceeded
the new defined reference range. After localization of
tumour tissue in the neck and reoperation the patients
showed a decrease in basal calcitonin concentrations
and after stimulation and were cured with respect to
the calcitonin concentration in serum (15). The use
of more sensitive calcitonin assays with a well defined
reference range for basal calcitonin concentrations
and after stimulation has shown that the cure rate of
medullary thyroid carcinoma by total thyroidectomy
is not as high as previously thought based on results
from radioimmunoassays. Similar results have been
reported by Kaplan et al. (16) from the screening of
multiple endocrine neoplasia 2A families. In archived
sera from patients who had undergone pentagastrin
tests, the more sensitive assays showed abnormally
elevated calcitonin concentrations in three patients
with C-cell hyperplasia 3—4 years or more before any
abnormality was detected by the standard calcitonin
radioimmunoassay. By using an immunoradiometric
assay, Guilloteau et al. (12) found, in eight affected
family members with medullary thyroid carcinoma, a
higher percentage of pathological basal (5/8) or stim-
ulated (8/8) calcitonin concentrations than with a
conventional radioimmunoassay (1/8 and 4/8 respec-
tively). These assays need to be tested more exten-
sively in familial screening of medullary thyroid car-
cinoma, but the present results favour the use of
highly sensitive two-site assays for calcitonin for de-
tecting any C-cell disease during familial screening
and during postsurgical follow-up. The established
reference ranges enable the detection of pathological
calcitonin concentrations in the pentagastrin test.
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